Brief: Verrica Pharmaceuticals Announces FDA Approval Of YCANTH Topical Solution As The First FDA Approved Treatment Of Pediatric And Adult Patients With Molluscum Contagiosum
21/07/2023 21:29
July 21 (Reuters) - Verrica Pharmaceuticals Inc
VRCA.O :
* VERRICA PHARMACEUTICALS ANNOUNCES FDA APPROVAL OF YCANTH™
(CANTHARIDIN) TOPICAL SOLUTION AS THE FIRST FDA APPROVED
TREATMENT OF PEDIATRIC AND ADULT PATIENTS WITH MOLLUSCUM
CONTAGIOSUM
* VERRICA PHARMACEUTICALS INC - VERRICA PLANS TO MAKE
YCANTH™
AVAILABLE BY SEPTEMBER 2023
Source text for Eikon: ID:nGNX3TfXcM
Further company coverage: VRCA.O
(Reuters.Briefs@thomsonreuters.com)
Recent news on Verrica Pharmaceuticals
See all newsVerrica Pharmaceuticals Inc reports results for the quarter ended June 30 - Earnings Summary
Verrica Pharma reports wider-than-expected Q2 adj loss per share
Verrica Pharmaceuticals Inc expected to post a loss of 38 cents a share - Earnings Preview
Verrica Pharmaceuticals Q1 revenue rises on YCANTH demand
Brief: Verrica Pharmaceuticals Announces Upcoming Presentation Of Phase 2 Data